Current Report Filing (8-k)
November 08 2017 - 4:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 8, 2017
CASCADIAN
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33882
|
|
26-0868560
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2601
Fourth Avenue, Suite 500
Seattle,
Washington 98121
(Address
of principal executive offices, including zip code)
(206)
801-2100
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02
|
Results of Operations
and Financial Condition.
|
On
November 8, 2017, Cascadian Therapeutics, Inc. (the “Company”) issued a press release regarding the Company’s
financial results for the quarter ended September 30, 2017 and providing a corporate update. A copy of the Company’s press
release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The
information in this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any other filing with
the U.S. Securities and Exchange Commission, whether made before, on or after the date hereof, regardless of any general incorporation
language in such filing, except as expressly set forth by specific reference in such filing.
Item
9.01
|
Financial Statements
and Exhibits.
|
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
|
CASCADIAN
THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/
Julia M. Eastland
|
|
|
Julia
M. Eastland
|
|
|
Chief
Financial Officer, Chief Business Officer and Secretary
|
Date:
November 8, 2017
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Oct 2023 to Oct 2024